Skip to content
Selzentry, Celsentri(maraviroc)
Celsentri, Selzentry (maraviroc) is a small molecule pharmaceutical. Maraviroc was first approved as Selzentry on 2007-08-06. It is used to treat HIV infections in the USA. It has been approved in Europe to treat HIV infections. The pharmaceutical is active against C-C chemokine receptor type 5.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
urogenital diseasesD000091642
immune system diseasesD007154
Trade Name
FDA
EMA
Selzentry (generic drugs available since 2022-02-07)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Maraviroc
Tradename
Company
Number
Date
Products
SELZENTRYViiV HealthcareN-022128 RX2007-08-06
4 products, RLD, RS
SELZENTRYViiV HealthcareN-208984 RX2016-11-04
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
selzentryNew Drug Application2022-11-30
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hiv infectionsEFO_0000764D015658B20
Agency Specific
FDA
EMA
Expiration
Code
MARAVIROC, SELZENTRY, VIIV HLTHCARE
2024-04-30PED
2023-10-30NPP
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AX: Other antivirals in atc
— J05AX09: Maraviroc
HCPCS
No data
Clinical
Clinical Trials
134 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B2010131418959
HivD006678O98.74519624
Healthy volunteers/patients—81—1—10
Acquired immunodeficiency syndromeD000163EFO_0000765B20——2428
InflammationD007249——11—2
Hiv-2D015498———112
ProteinuriaD011507HP_0000093R80———1—1
Heart disease risk factorsD000082742———1—1
AtherosclerosisD050197EFO_0003914I25.1———1—1
Hepatitis cD006526B19.2———1—1
Show 2 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv-1D015497—23—16
StrokeD020521EFO_0000712I63.9—31——3
Cardiovascular diseasesD002318EFO_0000319I98——1—12
Aids dementia complexD015526EFO_0002608—11——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Graft vs host diseaseD006086D89.8123———3
Covid-19D000086382U07.112———3
Hematopoietic stem cell transplantationD01838012———2
Hematologic neoplasmsD01933712———2
B-cell chronic lymphocytic leukemiaD015451C91.1—1———1
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_0000340—1———1
Hodgkin diseaseD006689C81—1———1
Follicular lymphomaD008224C82—1———1
Large b-cell lymphoma diffuseD016403C83.3—1———1
B-cell lymphomaD016393—1———1
Show 4 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colorectal neoplasmsD0151792———13
InfectionsD007239EFO_00005442————2
Pancreatic neoplasmsD010190EFO_0003860C251————1
Mycobacterium avium complexD0152691————1
HypertriglyceridemiaD015228EFO_00042111————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Immune reconstitution inflammatory syndromeD054019D89.3————11
SarcoidosisD012507EFO_0000690D80-D89————11
Neoplasm metastasisD009362EFO_0009708————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMARAVIROC
INNmaraviroc
Description
Maraviroc is a monocarboxylic acid amide obtained by formal condensation of the carboxy group of 4,4-difluorocyclohexanecarboxylic acid and the primary amino group of (1S)-3-[(3-exo)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropylamine. An antiretroviral drug, it prevents the interaction of HIV-1 gp120 and chemokine receptor 5 (CCR5) necessary for CCR5-tropic HIV-1 to enter cells. It has a role as an antiviral drug, a chemokine receptor 5 antagonist and a HIV fusion inhibitor. It is an azabicycloalkane, an organofluorine compound, a member of triazoles and a monocarboxylic acid amide.
Classification
Small molecule
Drug classantivirals; antivirals, chemokine receptor (CCR) antagonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1
Identifiers
PDB4MBS
CAS-ID376348-65-1
RxCUI620216
ChEMBL IDCHEMBL1201187
ChEBI ID63608
PubChem CID3002977
DrugBankDB04835
UNII IDMD6P741W8A (ChemIDplus, GSRS)
Target
Agency Approved
CCR5
CCR5
Organism
Homo sapiens
Gene name
CCR5
Gene synonyms
CMKBR5
NCBI Gene ID
1234
Protein name
C-C chemokine receptor type 5
Protein synonyms
C-C motif chemokine receptor 5 A159A, CD195, chemokine (C-C motif) receptor 5, chemokine receptor CCR5, chemokine recptor CCR5 Delta32, CHEMR13, HIV-1 fusion coreceptor, mutant C-C motif chemokine receptor
Uniprot ID
Q9UPA4
Mouse ortholog
—
—
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 5,639 documents
View more details
Safety
Black-box Warning
Black-box warning for: Selzentry
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
726 adverse events reported
View more details